| Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. | |
| | |
MedLine Citation:
|
PMID: 19104507 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We evaluated the potential use of intraoperative gelatin matrix hemostatic sealant (GMHS; FloSeal; Baxter Healthcare) embedded with macrophages (Mphi) transduced with murine interleukin (IL)-12 recombinant adenoviral vector (G/Mphi/AdmIL-12) for prevention of recurrence of prostate cancer following radical prostatectomy. Application of G/Mphi/AdmIL-12 resulted in significant suppression of tumor growth and spontaneous lung metastases, a statistically significant survival advantage of the G/Mphi/AdmIL-12-treated animals, more efficient trafficking of Mphi to lymph nodes draining from the prostate and generation of systemic natural killer cell activity and tumor-specific cytolytic T lymphocyte responses compared to the controls in a preclinical mouse model of residual prostate cancer. Our data recommend this treatment as a novel adjuvant for prevention of local recurrence of prostate cancer following radical prostatectomy. |
| | |
Authors:
|
K Tabata; M Watanabe; K Naruishi; K Edamura; T Satoh; G Yang; E Abdel Fattah; J Wang; A Goltsov; D Floryk; S D Soni; D Kadmon; T C Thompson |
Related Documents
:
|
11248627 - Does urethral-sparing prostatectomy risk residual prostate cancer? 20802467 - International society of urological pathology (isup) consensus conference on handling a... 19204997 - Central quadrant procurement of radical prostatectomy specimens. 12837427 - Zonal location of prostate cancer: significance for disease-free survival after radical... 16254107 - Aberrant expression of deltanp73 in benign and malignant tumours of the prostate: corre... 23527117 - Effect of cd44 binding peptide conjugated to an engineered inert matrix on maintenance ... |
Publication Detail:
|
Type: Journal Article Date: 2008-12-23 |
Journal Detail:
|
Title: Prostate cancer and prostatic diseases Volume: 12 ISSN: 1476-5608 ISO Abbreviation: Prostate Cancer Prostatic Dis. Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-09-01 Completed Date: 2009-11-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9815755 Medline TA: Prostate Cancer Prostatic Dis Country: England |
Other Details:
|
Languages: eng Pagination: 301-9 Citation Subset: IM |
Affiliation:
|
Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenoviridae
/
genetics Animals Cell Movement Cell Survival / drug effects Disease Models, Animal Gelatin Gene Therapy* Hemostatics / pharmacology Interleukin-12 / genetics*, immunology Macrophages / immunology, physiology* Male Mice Prostatic Neoplasms / mortality, pathology, therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Hemostatics; 187348-17-0/Interleukin-12; 9000-70-8/Gelatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advance...
Next Document: The use of one-channel water cystometry in patients with a spinal cord lesion: practicalities, clini...